
Quarterly report 2025-Q3
added 11-06-2025
Haemonetics Corporation Financial Statements 2011-2026 | HAE
Annual Financial Statements Haemonetics Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
3.06 B | 4.7 B | 4.24 B | 4.26 B | 2.45 B | 6.16 B | 4.64 B | 4.12 B | 2.2 B | 1.41 B | 2.17 B | 1.63 B | 2.05 B | 1.82 B | 1.76 B |
Shares |
50.3 M | 50.7 M | 50.8 M | 51 M | 50.7 M | 51.8 M | 52.9 M | 52.8 M | 51.5 M | 50.9 M | 52.1 M | 52.4 M | 52.3 M | 50.7 M | 51.2 M |
Historical Prices |
60.9 | 92.6 | 83.5 | 83.5 | 48.4 | 114 | 107 | 98.9 | 64.7 | 39.9 | 31.6 | 39.6 | 37.9 | 41.9 | 32.5 |
Net Income |
168 M | 118 M | 115 M | 43.4 M | 79.5 M | 76.5 M | 55 M | 45.6 M | -26.3 M | -55.6 M | 16.9 M | 35.1 M | 38.8 M | 66.9 M | 80 M |
Revenue |
1.36 B | 1.31 B | 1.17 B | 993 M | 870 M | 988 M | 968 M | 904 M | 886 M | 909 M | 910 M | 938 M | 892 M | 728 M | 677 M |
Cost of Revenue |
612 M | 618 M | 554 M | 488 M | 473 M | 504 M | 550 M | 492 M | 508 M | - | - | - | - | - | - |
Gross Profit |
749 M | 692 M | 615 M | 506 M | 398 M | 488 M | 439 M | 412 M | 378 M | 406 M | 434 M | 468 M | 428 M | 369 M | 355 M |
Operating Income |
222 M | 165 M | 156 M | 80.8 M | 89.7 M | 103 M | 83.5 M | 56.2 M | -19.4 M | -43.9 M | 40.5 M | 46.4 M | 56.4 M | 88.8 M | 111 M |
Interest Expense |
-9.75 M | -13 M | -14.6 M | -17.1 M | -16.8 M | -16.2 M | -9.91 M | -4.52 M | -8.1 M | -9.47 M | -9.38 M | -10 M | -6.54 M | 740 K | 6 K |
EBITDA |
337 M | 262 M | 249 M | 178 M | 174 M | 214 M | 193 M | 145 M | 70.4 M | 46 M | 127 M | 129 M | 122 M | 139 M | 159 M |
Operating Expenses |
527 M | 527 M | 459 M | 425 M | 308 M | 384 M | 355 M | 356 M | 398 M | 450 M | 394 M | 421 M | 372 M | 280 M | 245 M |
General and Administrative Expenses |
437 M | 432 M | 377 M | 340 M | 275 M | 284 M | 285 M | 317 M | 302 M | 317 M | 259 M | 365 M | 323 M | 245 M | 206 M |
All numbers in USD currency
Quarterly Income Statement Haemonetics Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
47.6 M | 48.1 M | 48.2 M | 50.3 M | 50.9 M | 50.9 M | 50.8 M | 50.8 M | 50.7 M | 50.5 M | 50.4 M | 50.5 M | 51 M | 51.2 M | 51.1 M | - | 51 M | 51 M | 50.9 M | 50.8 M | 50.8 M | 50.7 M | 50.4 M | 50.6 M | 50.6 M | 50.8 M | 51 M | 51.4 M | 51.4 M | 51.6 M | 52.3 M | 53.1 M | 52.6 M | 52.4 M | 52.3 M | 51.7 M | 51.4 M | 51.2 M | 50.9 M | 50.7 M | 50.9 M | 51 M | 51.7 M | 51.4 M | 51.5 M | 51.6 M | 52 M | 51.7 M | 51.5 M | 51.4 M | 51 M | 51.7 M | 51.4 M | 51.2 M | 50.6 M | 50.2 M | 50.8 M | 25.6 M | 25.3 M |
Net Income |
38.7 M | 34 M | - | 37.5 M | 33.8 M | 38.4 M | - | 31.2 M | 24.9 M | 41 M | - | 32.9 M | 33.2 M | 19.9 M | - | - | 14.9 M | -4.45 M | -4.45 M | 31.9 M | 31.9 M | 48.1 M | 10.5 M | 29.9 M | 29.9 M | 37.5 M | -8.48 M | -8.48 M | 18.3 M | 18.7 M | 11.9 M | -6.55 M | 20.1 M | 20.1 M | 20.1 M | 15.4 M | 15.4 M | 19.8 M | -10.3 M | -59.4 M | -59.4 M | 12.9 M | -267 K | 16 M | 16 M | 7.49 M | -3.65 M | 16.3 M | 16.3 M | 16.5 M | -7.87 M | 9.9 M | 9.9 M | 6.55 M | 9.79 M | 18.3 M | 18.3 M | 13.9 M | 16.9 M |
Revenue |
327 M | 321 M | - | 349 M | 346 M | 336 M | - | 336 M | 318 M | 311 M | - | 305 M | 297 M | 261 M | - | - | 240 M | 468 M | 225 M | 240 M | 240 M | 209 M | 196 M | 259 M | 259 M | 253 M | 238 M | 247 M | 247 M | 242 M | 234 M | 234 M | 225 M | 211 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
133 M | 129 M | - | 155 M | 158 M | 161 M | - | 158 M | 148 M | 144 M | - | 147 M | 140 M | 119 M | - | - | 117 M | 238 M | - | 120 M | 120 M | 104 M | 106 M | 131 M | 131 M | 126 M | 123 M | 136 M | 136 M | 130 M | - | 123 M | 121 M | 119 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
195 M | 192 M | - | 194 M | 187 M | 175 M | - | 178 M | 171 M | 167 M | - | 159 M | 158 M | 142 M | - | - | 123 M | 231 M | 81.8 M | 120 M | 120 M | 106 M | 90 M | 128 M | 128 M | 127 M | 116 M | 111 M | 111 M | 112 M | 104 M | 111 M | 105 M | 91.7 M | 91.7 M | 101 M | 101 M | 104 M | 91.1 M | 109 M | 109 M | 105 M | 103 M | 112 M | 112 M | 108 M | 106 M | 122 M | 122 M | 120 M | 111 M | 113 M | 113 M | 102 M | 90.1 M | 95.9 M | 95.9 M | 89.9 M | 88.7 M |
Operating Income |
58.5 M | 53.9 M | - | 59 M | 51.7 M | 39.8 M | - | 46 M | 35.3 M | 53.7 M | - | 43.3 M | 46.7 M | 30.8 M | - | - | 24.5 M | 25.9 M | -21.2 M | 40.4 M | 40.4 M | 58.8 M | 11.7 M | 40.9 M | 40.9 M | 49.7 M | -13.3 M | 28.3 M | 28.3 M | 26.1 M | 14.3 M | 1.01 M | 24.3 M | 16.6 M | 16.6 M | 21.2 M | 21.2 M | 24.8 M | -7.88 M | -61.2 M | -61.2 M | 19.2 M | 3.61 M | 18.3 M | 18.3 M | 12.4 M | -1.67 M | 17.6 M | 17.9 M | 23.4 M | -6.61 M | 15.7 M | 15.7 M | 9.9 M | 13.1 M | 25.3 M | 25.3 M | 18.6 M | 23.9 M |
Interest Expense |
-7.21 M | -8.7 M | - | -9.11 M | -6.99 M | 6.96 M | - | -1.95 M | -2.47 M | -2.07 M | - | -1.06 M | -5.67 M | -5.27 M | - | - | -4.59 M | -8.99 M | - | -3.05 M | -3.05 M | -3.83 M | -3.74 M | -3.08 M | -3.08 M | -4.65 M | -4.42 M | -2.86 M | -2.86 M | -3.04 M | - | -806 K | -1.4 M | -1.36 M | - | -2.28 M | -6.41 M | -4.14 M | - | -2.14 M | -6.76 M | -4.62 M | - | -2.31 M | -7.5 M | -5.19 M | - | -2.85 M | -8.04 M | -5.18 M | - | -2.54 M | -3.52 M | -975 K | - | 111 K | 370 K | 106 K | - |
EBITDA |
86.7 M | 82.6 M | - | 74.2 M | 80.9 M | 68.9 M | - | 60.2 M | 48.9 M | 76.7 M | - | 56.4 M | 59.6 M | 53.2 M | - | - | 35.9 M | 74.5 M | -21.2 M | 48.2 M | 103 M | 100 M | 32.4 M | 40.9 M | 122 M | 104 M | 14.1 M | 28.3 M | 108 M | 77.8 M | 14.3 M | 1.01 M | 24.3 M | 38.4 M | 16.6 M | 21.2 M | 88.7 M | 70 M | -7.88 M | -61.2 M | 6.54 M | 64.2 M | 3.61 M | 18.3 M | 82.2 M | 54 M | -1.67 M | 17.6 M | 76.9 M | 61.7 M | -6.61 M | 15.7 M | 62.5 M | 38.5 M | 13.1 M | 25.3 M | 62.6 M | 43.2 M | 23.9 M |
Operating Expenses |
136 M | 138 M | - | 135 M | 136 M | 135 M | - | 132 M | 135 M | 114 M | - | 115 M | 111 M | 111 M | - | - | 98 M | 205 M | - | 79.8 M | 79.8 M | 47 M | 78.3 M | 87.1 M | 87.1 M | 77.3 M | 129 M | 82.9 M | 82.9 M | 85.8 M | - | 110 M | 80.3 M | 75.1 M | - | 79.9 M | 258 M | 178 M | - | 170 M | 355 M | 185 M | - | 93.4 M | 297 M | 204 M | - | 104 M | 318 M | 214 M | - | 97.4 M | 266 M | 169 M | - | 70.6 M | 207 M | 136 M | - |
General and Administrative Expenses |
102 M | 111 M | - | 106 M | 107 M | 108 M | - | 112 M | 115 M | 93.5 M | - | 94.7 M | 92 M | 92.2 M | - | - | 75.8 M | 167 M | - | 65.6 M | 73.4 M | 71.7 M | 69.5 M | 78.3 M | 78.3 M | 69.8 M | 73 M | 73.9 M | 73.9 M | 77.2 M | - | 97.9 M | 72.8 M | 66.9 M | - | 71.4 M | 230 M | 159 M | - | 78.9 M | 241 M | 162 M | - | 82.5 M | 259 M | 177 M | - | 89.6 M | 278 M | 188 M | - | 86.8 M | 235 M | 149 M | - | 61.4 M | 180 M | 119 M | - |
All numbers in USD currency
Main types of financial statements Haemonetics Corporation HAEFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Haemonetics Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 19.75 | 0.08 % | $ 10.1 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.31 | -1.01 % | $ 168 M | ||
|
Alcon
ALC
|
$ 81.61 | 0.59 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
$ 37.33 | 1.03 % | $ 1.75 B | ||
|
electroCore
ECOR
|
$ 7.32 | 3.15 % | $ 40.4 K | ||
|
Repro Med Systems
KRMD
|
$ 5.5 | 0.92 % | $ 251 M | ||
|
AngioDynamics
ANGO
|
$ 10.06 | 0.79 % | $ 411 M | ||
|
ICU Medical
ICUI
|
$ 152.09 | 1.37 % | $ 3.71 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.05 | 0.12 % | $ 166 M | ||
|
The Cooper Companies
COO
|
$ 81.06 | 0.85 % | $ 16.1 B | ||
|
Masimo Corporation
MASI
|
$ 136.75 | 0.37 % | $ 7.29 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.53 | -1.71 % | $ 22.5 M | ||
|
Glaukos Corporation
GKOS
|
$ 121.38 | 2.03 % | $ 5.88 B | ||
|
Merit Medical Systems
MMSI
|
$ 80.86 | 0.78 % | $ 4.71 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
iRhythm Technologies
IRTC
|
$ 150.0 | 0.67 % | $ 4.68 B | ||
|
LeMaitre Vascular
LMAT
|
$ 84.05 | 0.23 % | $ 1.89 B | ||
|
Intuitive Surgical
ISRG
|
$ 509.54 | 0.39 % | $ 181 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
STERIS plc
STE
|
$ 261.63 | - | $ 25.8 B | ||
|
Microbot Medical
MBOT
|
$ 1.87 | 0.27 % | $ 19.1 M | ||
|
Nephros
NEPH
|
$ 4.39 | - | $ 45.6 M | ||
|
Utah Medical Products
UTMD
|
$ 61.01 | -1.04 % | $ 221 M | ||
|
Milestone Scientific
MLSS
|
$ 0.3 | 1.88 % | $ 23.9 M | ||
|
Envista Holdings Corporation
NVST
|
$ 23.43 | 0.24 % | $ 4.03 B | ||
|
OraSure Technologies
OSUR
|
$ 2.84 | 1.61 % | $ 211 M | ||
|
Pro-Dex
PDEX
|
$ 39.8 | 1.0 % | $ 131 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.26 | 4.69 % | $ 685 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 200.32 | -0.38 % | $ 57.6 B | ||
|
Repligen Corporation
RGEN
|
$ 155.76 | -0.39 % | $ 8.68 M | ||
|
ResMed
RMD
|
$ 252.47 | -2.0 % | $ 36.9 B | ||
|
BioLife Solutions
BLFS
|
$ 22.64 | 0.27 % | $ 1.04 B | ||
|
Stereotaxis
STXS
|
$ 2.34 | - | $ 189 M | ||
|
Retractable Technologies
RVP
|
$ 0.71 | - | $ 21.3 M | ||
|
STAAR Surgical Company
STAA
|
$ 19.19 | 1.32 % | $ 943 M | ||
|
Teleflex Incorporated
TFX
|
$ 105.17 | -0.27 % | $ 4.93 B | ||
|
West Pharmaceutical Services
WST
|
$ 230.5 | -0.86 % | $ 16.8 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 12.27 | 0.03 % | $ 2.49 B |